share_log

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87

Canaccord Genuity維持對Arcturus Therapeutics的買入,將目標股價上調至87美元
Moomoo 24/7 ·  03/11 07:51

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target from $81 to $87.

Canaccord Genuity分析師惠特尼·伊傑姆維持Arcturus Therapeutics(納斯達克股票代碼:ARCT)的買入並將目標股價從81美元上調至87美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論